On February 26, 2018, AMCP joined 11 organizations in letter to the OIG in support of establishing a safe harbor provision that would encourage the development of additional value-based contracts for the Medicare and Medicaid populations.
On January 30, 2018, AMCP delivered remarks to the FDA at an opioid policy steering committee meeting. AMCP commended the FDA for establishing the OPSC and for seeking public input to help identify key areas of focus that the FDA can address. AMCP focused on the following three areas; REMS; Labeling, Packaging, Storage, and Disposal; and Additional Focus Areas where AMCP feels that the FDA can be actively involved in combating the opioid epidemic.
AMCP submitted comments to CMS in response to its proposed rule for technical changes to the Medicare Prescription Drug Benefit Program. AMCP offered comments on the following areas of the proposed rule: drug management programs, Medication Therapy Management, benefit design & utilization management, health information technology & data interoperability, and fraud, waste, & abuse.